GL1X · GenesisL1 explorer

UniProt P27348

14-3-3 protein theta (P27348)

14-3-3 protein theta (UniProt P27348): 12 experimental structures and 1 predicted model on GenesisL1, 2 ligands bound, 33 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.

UniProt
P27348
Protein
14-3-3 protein theta
Experimental structures
12
Predicted models
1
Ligands
2
Pockets
33 · 4 records with a druggable one

Structures

13 records of P27348 in the MolNFT archive: 12 experimental, 1 predicted.

EntryTitleMethodChainsLigandsPockets
2BTP14-3-3 Protein Theta (Human) Complexed to Peptidex-ray diffractionA, B——
2BTP14-3-3 protein theta (human) complexed to peptidex-ray diffractionA, B——
5IQP14-3-3 protein tau isoformx-ray diffractionA, BSO43 (best 0.55)
5IQP14-3-3 protein tau isoformx-ray diffractionA, B——
6BCRComplex of 14-3-3 theta with an IRSP53 peptide phosphorylated at T340x-ray diffractionA, B, E, FMG—
6BD2Complex of 14-3-3 theta with an IRSp53 peptide doubly-phosphorylated at T340 and S366x-ray diffractionA, B—7 (best 0.62)
6BD2Complex of 14-3-3 theta with an IRSP53 peptide doubly-phosphorylated at T340 and S366x-ray diffractionA, B——
6BQTComplex of 14-3-3 theta with an IRSp53 peptide doubly-phosphorylated at T340 and T360x-ray diffractionA, B, D, E, G, H, J, K—20 (best 0.77)
6BQTComplex of 14-3-3 theta with an IRSP53 peptide doubly-phosphorylated at T340 and T360x-ray diffractionA, B, D, E, G, H, J, K——
6KZG14-3-3 protein in complex with cic S301 phosphorylated peptidex-ray diffractionA, B——
6KZH14-3-3 protein in Complex with CIC S173 phosphorylated peptidex-ray diffractionA, B—3 (best 0.60)
6KZH14-3-3 protein in complex with cic S173 phosphorylated peptidex-ray diffractionA, B——
P27348AlphaFold monomer V2.0 prediction for 14-3-3 protein theta (P27348)predictedA——

Ligands

  • MG · Magnesium ion · in 1 record
  • SO4 · Sulfate ion · in 1 record

Experiment against prediction

Elsewhere

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.